Warning: The NCBI web site requires JavaScript to function. more...
Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.
Huigen MC, van Ham PM, de Graaf L, Kagan RM, Boucher CA, Nijhuis M.
Retrovirology. 2008 Feb 13;5:20.
Related citations
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G.
PLoS Med. 2007 Dec;4(12):e335.
NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S, Baldanti F, Campanini G, Cancio R, Belfiore A, Maga G, Gerna G.
Antiviral Res. 2007 Nov;76(2):99-103. Epub 2007 Jul 2.
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR.
J Virol. 2006 Jul;80(14):7020-7.
Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW.
J Virol. 2007 Aug;81(15):7852-9. Epub 2007 May 16.
Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
Trivedi V, Von Lindern J, Montes-Walters M, Rojo DR, Shell EJ, Parkin N, O'Brien WA, Ferguson MR.
AIDS Res Hum Retroviruses. 2008 Oct;24(10):1291-300.
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW.
Antimicrob Agents Chemother. 2007 Jan;51(1):48-53. Epub 2006 Nov 6.
Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
Prado JG, Franco S, Matamoros T, Ruiz L, Clotet B, Menéndez-Arias L, Martínez MA, Martinez-Picado J.
Virology. 2004 Aug 15;326(1):103-12.
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.
Svicher V, Sing T, Santoro MM, Forbici F, Rodríguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF.
J Virol. 2006 Jul;80(14):7186-98.
Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC, Zazzi M.
J Infect Dis. 2002 Apr 1;185(7):898-904. Epub 2002 Mar 11.
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W.
J Virol. 2004 Jul;78(14):7545-52.
Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness.
Lu J, Whitcomb J, Kuritzkes DR.
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):20-3.
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Parikh UM, Bacheler L, Koontz D, Mellors JW.
J Virol. 2006 May;80(10):4971-7.
Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL, Imamichi T, Sarafianos SG, Arnold E, Hughes SH.
J Virol. 2004 Sep;78(18):9987-97.
A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
García-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, Kaplan JE, Heneine W.
J Virol. 2003 May;77(10):5685-93.
Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, Brun-Vézinet F, Perrin L.
J Virol. 1998 May;72(5):3520-3.
Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B.
Virology. 2001 May 10;283(2):294-305.
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.
Mbisa JL, Gupta RK, Kabamba D, Mulenga V, Kalumbi M, Chintu C, Parry CM, Gibb DM, Walker SA, Cane PA, Pillay D.
Retrovirology. 2011 May 11;8:31.
Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
van der Hoek L, Back N, Jebbink MF, de Ronde A, Bakker M, Jurriaans S, Reiss P, Parkin N, Berkhout B.
J Virol. 2005 Mar;79(6):3536-43.
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.
Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on